About Atossa Therapeutics
Atossa Therapeutics is a publicly listed company based in Seattle (United States) founded in 2009 by Steven Quay. Drugs for breast cancer treatment and prevention are developed. Atossa Therapeutics has raised $13.52 million across 7 funding rounds from investors including Aspire Capital. The company has 15 employees. Its chief executive, as recorded, is Steven Quay. Atossa Therapeutics offers products and services including (Z)-endoxifen and EVANGELINE Study Program. Its focus areas include Life Sciences, Drug Delivery, Implants and Oncology. Its legal entity is Atossa Therapeutics, Inc. Its competitors include Daré Bioscience, Olema Oncology and Puma Biotechnology; 2 of its 3 listed competitors have raised funding.
Company details
Founded in 2009 and based in Seattle, United States, focus is placed on biotechnology for oncology. Endoxifen is developed in topical and oral forms to address breast cancer prevention and treatment. A nasal spray and additional therapeutic are pursued for COVID-19 management. Operations center on drug development within the pharmaceutical sector.
- Headquarters Seattle, United States
- Employees 15
- Founders Steven Quay
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website atossatherapeutics.com
- Social LinkedIn X Facebook
- Legal Name Atossa Therapeutics, Inc.
- Net Profit-$34.77 M (USD)-36.33as on Dec 31, 2025
- EBITDA-$37.13 M (USD)-34.49as on Dec 31, 2025
- Total Equity Funding$13.52M (USD)
in 7 rounds
- Latest Funding Round$21M (USD), Post-IPO
Jan 2021
- Investors
- Employee Count15
Products & Services of Atossa Therapeutics
Atossa Therapeutics offers a comprehensive portfolio of products and services, including (Z)-endoxifen and EVANGELINE Study Program.
Therapy for breast cancer prevention and treatment in clinical trials.
Phase 2 trial for ER+ breast cancer neoadjuvant treatment.
Funding Insights of Atossa Therapeutics
Atossa Therapeutics has successfully raised a total of $13.52M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $21 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.52M
- Total Rounds 7
- Last Round Post-IPO — $21M
- First Round $173,000
(Jan 2010)
- Investors Count 1
All 7 funding rounds of Atossa Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $21M | Post-IPO | – | – | – |
| Apr 2013 | $1M | Post-IPO | – | – | – |
| Mar 2013 | $1M | Post-IPO | – | – | |
| Jun 2011 | $6.6M | Series A | – | – | – |
| Jun 2011 | $6.57M | Series A | – | – | – |
| Sep 2010 | $173,000 | Seed | – | – | – |
| Jan 2010 | $173,000 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Atossa Therapeutics
Atossa Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Aspire Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| aspirecapital.com |
Investor details for Atossa Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Atossa Therapeutics
1 people are tracked at Atossa Therapeutics (1 in leadership); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
Steven Quay | Founder & CEO | Leadership |
Complete people profiles for Atossa Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Atossa Therapeutics
Atossa Therapeutics is a publicly listed company on the NASDAQ with ticker symbol ATOS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Nov 2012
- Listed onNASDAQ: ATOS
- Listed entityAtossa Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS04962H7044
- Share price$2.56 (+7.17% on the day) · 2026-10-13
- Market capitalisation$25.5M
- EPS (diluted, trailing year)$-4.34
- Volume (last session)71,414
Financials of Atossa Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$34.8M | -$37.1M | |
| 2024 | -$25.5M | -$27.6M | |
| 2023 | -$30.1M | -$31.4M | |
| 2022 | -$27.0M | -$27.7M | |
| 2021 | -$20.6M | -$20.5M |
Detailed financial statements for Atossa Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Atossa Therapeutics
4 dated milestones of Atossa Therapeutics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Atossa Therapeutics is founded.
- Funding First funding round of $173K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $21.0M.
Competitors of Atossa Therapeutics
Atossa Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Daré Bioscience, Olema Oncology and Puma Biotechnology.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| darebioscience.com | 2005 | San Diego, United States | 30 | Non-hormonal pharmaceutical products for female contraceptives are developed. | ||
| olema.com | 2007 | San Francisco, United States | $139M | 74 | Drug therapeutics for breast cancer treatment are developed. | |
| pumabiotechnology.com | 2010 | Los Angeles, United States | $60M | 193 | Tyrosine kinase inhibitors for breast cancer are developed. |
Detailed competitors of Atossa Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Atossa Therapeutics
The website of Atossa Therapeutics (atossatherapeutics.com) receives about 3.6K visits a month and ranks #6,707,144 among all websites worldwide, #6,714 in Biotechnology and Pharmaceuticals.
- Monthly visits3.6K
▲ 62.3% vs previous month
- Global rank#6,707,144
among all websites
- Category rank#6,714
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit2.1
- Average visit34 sec
- DevicesDesktop 52% · Mobile 48%
Websites whose visitors overlap most with Atossa Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
drug-dev.com | drug-dev.com | 100% | #896,353 | – |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Atossa Therapeutics (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Atossa Therapeutics
Complete news archive for Atossa Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Atossa Therapeutics
Atossa Therapeutics was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Atossa Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Steven Quay is the CEO of Atossa Therapeutics, as recorded in our data. They have also founded this company.
Atossa Therapeutics is a funded company, having raised a total of $13.52M across 7 funding rounds to date. The company's 1st funding round was a Seed of $173K, raised on Jan 2010.
Atossa Therapeutics has 15 employees.
Founded in 2009 and based in Seattle, United States, focus is placed on biotechnology for oncology. Endoxifen is developed in topical and oral forms to address breast cancer prevention and treatment. A nasal spray and additional therapeutic are pursued for COVID-19 management. Operations center on drug development within the pharmaceutical sector.
Atossa Therapeutics's top competitors include Daré Bioscience, Puma Biotechnology and Olema Oncology.
Atossa Therapeutics offers (Z)-endoxifen and EVANGELINE Study Program.
Yes, Atossa Therapeutics is publicly traded on NASDAQ under the ticker symbol ATOS.
Atossa Therapeutics has 1 investor. Key investors include Aspire Capital.
Atossa Therapeutics operates through Atossa Therapeutics, Inc..